Kevin Boyle, Alaunos Therapeutics CEO

Zio­pharm re­brands to Alaunos, clos­es Boston of­fice with new CEO at the reins

A lit­tle over a year af­ter fac­ing an ac­tivist at­tack that saw for­mer CEO Lau­rence Coop­er sur­vive but re­tire a few months lat­er, Zio­pharm On­col­o­gy will un­der­go a re­brand­ing and re­struc­tur­ing.

Its new com­pa­ny name will be Alaunos Ther­a­peu­tics, the biotech an­nounced Thurs­day, aim­ing to put its check­ered past be­hind it. In ad­di­tion, Alaunos has closed its Boston of­fice and will move its head­quar­ters to Hous­ton — it’s un­clear whether this will re­sult in sub­stan­tial lay­offs.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.